Course Experts: Yong Jun (Eric) Bae, PharmD, MBA, BCOP and Emily Tiao, PharmD, BCOP

Course Description: This course addresses risk groups and therapeutic aims in MDS, and reviews recent literature and related medication management on novel agents in low-risk MDS.

[DFCI_KEYWORDS] Chronic Lymphocytic Leukemia (CLL), Bruton’s Tyrosine Kinase (BTK) Inhibitors, Pathophysiology, Prognostic Markers, Genetic Markers, Cytogenetics, Ibrutinib, Acalabrutinib, Zanubrutinib, Pirtobrutinib, Lymphocytes, Lymphadenopathy, Venetoclax, Obinutuzumab, Rituximab, Fludarabine, Bendamustine, Antiplatelet, Anticoagulation, Leukocytosis